Shares of Moderna Inc. have soared so much that the biotechnology companys valuation is unjustifiable on a fundamental basis, said analyst Geoff Meacham on Tuesday, as his analysis suggests the stock should be priced about 75% below current levels.On Monday,…

Click here to view the original article.